Cover Image
Market Research Report

Osteoarthritis (OA): Opportunity Assessments, Epidemiology Forecast, Market Dynamics, Pipeline Analysis, H2 2018

Published by GervanoRA Data Services LLP Product code 769580
Published Content info 227 Pages
Delivery time: 1-2 business days
Price
Back to Top
Osteoarthritis (OA): Opportunity Assessments, Epidemiology Forecast, Market Dynamics, Pipeline Analysis, H2 2018
Published: January 11, 2019 Content info: 227 Pages
Description

GervanoRA's pipeline analysis and opportunity assessment report "Osteoarthritis (OA): Opportunity Assessments, Epidemiology Forecast, Market Dynamics, Pipeline Analysis, H2 2018" analyzed and assessed Osteoarthritis (OA) pipeline molecules for the opportunities in the competitive space by covering all the pipeline molecules in different stages of development and all the companies which are actively involved in Osteoarthritis (OA) industry. To provide systematic pipeline analytics, we have segregated total pipeline molecules into different segments like Pipeline Molecules by Geography, Pipeline Molecules by Drug Class, Pipeline Molecules by Mechanism of Action and Pipeline Molecules by Stage of development. Report is more focused to provide competitive opportunities by assessing and providing in-depth analytics on

  • Unmet needs and Opportunities
  • Epidemiology and Epidemiology forecast 2019 - 2025
  • Market Dynamics with Coverage of Deals (Mergers, Acquisitions, Partnering, Collaborations etc.)
  • Patent Analysis of Pipeline Molecules
  • Pipeline Analysis and Estimated Pipeline Drug Approval Time lines
  • Clinical Trials Summary
  • Current and Future Competitive Landscape
  • Key Company Profiles with SWOT Analysis
  • Emerging Company Profiles with Opportunity Assessments
  • Pipeline Drug Descriptions along with Development milestones (Past and Future)
  • University Pipeline Molecules & In-Licensing/Out Licensing Opportunities

Report helps clients to refine the commercial opportunities from the existing treatment armamentarium to pipeline assets, deals, and deal comparables. Even it helps in identifying the most relevant actors in the field for partnering deals.

Table of Contents
Product Code: GERPH225

TABLE OF CONTENTS

1. INTRODUCTION

  • 1.1. REPORT DESCRIPTION
  • 1.2. METHODOLOGY
  • 1.3. UPCOMING AND OTHER AVAILABLE PIPELINE ANALYSIS REPORTS
  • 1.4. ABOUT US: GERVANORA DATA SERVICES

2. EXECUTIVE SUMMARY

  • 2.1. REPORT MAJOR FINDINGS
  • 2.2. KEY EVENTS IN OSTEOARTHRITIS COMPETITIVE SPACE

3. DISEASE OVERVIEW

  • 3.1. DISEASE DEFINITION AND SYMPTOMS
  • 3.2. DISEASE CAUSE AND CLASSIFICATION
  • 3.3. DISEASE DIAGNOSIS
  • 3.4. TREATMENT ALGORITHM & GUIDELINES
  • 3.5. EPIDEMIOLOGY AND DISEASE BURDEN
  • 3.6. EPIDEMIOLOGY FORECAST
    • 3.6.1. FORECAST METHODOLOGY AND ASSUMPTION
    • 3.6.2. PROBABILISTIC EPIDEMIOLOGY FORECAST

4. MARKET OVERVIEW

  • 4.1. DEALS (MERGERS/ ACQUISITIONS / COLLABORATIONS)
  • 4.2. NEW PRODUCT APPROVAL IN THE US (FDA) SINCE 2000
  • 4.3. NEW PRODUCT APPROVAL INTERNATIONAL (EX. US) SINCE 2010
  • 4.4. PATENT ANALYSIS (EXPIRES AND GENERICIZATION)

5. PIPELINE ANALYSIS

  • 5.1. PIPELINE ANALYSIS BY STAGE OF DEVELOPMENT
    • 5.1.1. PHASE 3 MOLECULES
    • 5.1.2. PHASE 2 MOLECULES
    • 5.1.3. PHASE 1 MOLECULES
    • 5.1.4. PRECLINICAL MOLECULES
    • 5.1.5. EARLY R&D (DISCOVERY) MOLECULES
    • 5.1.6. TERMINATED AND INACTIVE MOLECULES
  • 5.2. PIPELINE ANALYSIS BY GEOGRAPHY
    • 5.2.1. UNMET NEEDS AND OPPORTUNITIES
  • 5.3. PIPELINE ANALYSIS BY ROUTE OF ADMINISTRATION
    • 5.3.1. UNMET NEEDS AND OPPORTUNITIES
  • 5.4. PIPELINE ANALYSIS BY DRUG CLASS
    • 5.4.1. UNMET NEEDS AND OPPORTUNITIES
  • 5.5. PIPELINE ANALYSIS BY MECHANISM OF ACTION
    • 5.5.1. UNMET NEEDS AND OPPORTUNITIES

6. ESTIMATED DRUG APPROVAL TIMELINES

  • 6.1. METHODOLOGY
    • 6.1.1. ESTIMATED APPROVAL TIMELINES US & EX-US

7. OSTEOARTHRITIS CLINICAL TRIALS SUMMARY

  • 7.1. OSTEOARTHRITIS PIPELINE ANALYSIS BY CLINICAL TRIAL RESULTS
    • 7.1.1. KEY PHASE III RESULTS
    • 7.1.2. KEY PHASE II RESULTS
  • 7.2. ONGOING CLINICAL TRIALS SUMMARY
    • 7.2.1. PHASE III ONGOING CLINICAL TRIALS
    • 7.2.2. PHASE II/III ONGOING CLINICAL TRIALS
    • 7.2.3. PHASE II ONGOING CLINICAL TRIALS
    • 7.2.4. PHASE I ONGOING CLINICAL TRIALS
  • 7.3. PLANNED CLINICAL TRIALS SUMMARY
    • 7.3.1. PHASE III PLANNED CLINICAL TRIALS
    • 7.3.2. PHASE II PLANNED CLINICAL TRIALS
    • 7.3.3. PHASE I PLANNED CLINICAL TRIALS
  • 7.4. RECENTLY COMPLETED CLINICAL TRIALS SUMMARY
    • 7.4.1. RECENTLY COMPLETED PHASE III CLINICAL TRIALS (2015-2018)
    • 7.4.2. RECENTLY COMPLETED PHASE II/III CLINICAL TRIALS (2015-2018)
    • 7.4.3. RECENTLY COMPLETED PHASE II CLINICAL TRIALS (2015-2018)
    • 7.4.4. RECENTLY COMPLETED PHASE II/I CLINICAL TRIALS (2015-2018)
    • 7.4.5. RECENTLY COMPLETED PHASE I CLINICAL TRIALS (2015-2018)
  • 7.5. POST-MARKETING SURVEILLANCE (PMS) STUDIES

8. CURRENT AND FUTURE COMPETITIVE LANDSCAPE

  • 8.1. COMPANIES
    • 8.1.1. ESTABLISHED COMPANIES
    • 8.1.2. KEY COMPANY PROFILES AND SWOT
      • 8.1.2.1. ASTRAZENECA PLC
      • 8.1.2.2. ELI LILLY AND COMPANY
      • 8.1.2.3. PFIZER PHARMACEUTICALS
      • 8.1.2.4. FLEXION THERAPEUTICS
      • 8.1.2.5. VERICEL CORPORATION
      • 8.1.2.6. IROKO PHARMACEUTICALS
      • 8.1.2.7. ANIKA THERAPEUTICS
      • 8.1.2.8. HORIZON PHARMA, PLC
      • 8.1.2.9. NUVO PHARMACEUTICALS, INC
    • 8.1.3. EMERGING COMPANIES
      • 8.1.3.1. KITOV PHARMACEUTICALS
      • 8.1.3.2. KOLON TISSUEGENE, INC.
      • 8.1.3.3. SAMUMED, LLC
      • 8.1.3.4. OLATEC THERAPEUTICS LLC
      • 8.1.3.5. ORTHOTROPHIX, INC
      • 8.1.3.6. CALOSYN PHARMA, INC.
      • 8.1.3.7. TECHFIELDS PHARMA CO. LTD
      • 8.1.3.8. EMBER THERAPEUTICS
      • 8.1.3.9. ZYNERBA PHARMACEUTICALS
      • 8.1.3.10. BONE THERAPEUTICS SA
      • 8.1.3.11. LEVOLTA PHARMACEUTICALS INC.
      • 8.1.3.12. CENTREXION THERAPEUTICS CORPORATION
      • 8.1.3.13. AMPIO PHARMACEUTICALS
      • 8.1.3.14. SYMIC BIOMEDICAL
      • 8.1.3.15. PARADIGM BIOPHARMA LTD

9. ABBREVIATIONS

LIST OF TABLES

  • TABLE 01: OA GLOBAL EPIDEMIOLOGY (2017) AND FORECAST (2018-2025)
  • TABLE 02: OA US EPIDEMIOLOGY (2017) AND FORECAST (2018-2025)
  • TABLE 03: TOP 11 OSTEOARTHRITIS DEALS RANKED BY TOTAL DEAL VALUE ($ M)
  • TABLE 04: TOTAL DEALS IN CHRONOLOGICAL ORDER (2018-2004)
  • TABLE 05: FDA APPROVED DRUGS FOR OSTEOARTHITIS (2000-2018)
  • TABLE 06: FDA APPROVED DRUGS FOR OSTEOARTHRITIS (PATENT ANALYSIS)
  • TABLE 07: ZILRETTA US GRANTED PATENTS, FLEXION
  • TABLE 08: ZILRETTA US PATENT APPLICATIONS, FLEXION
  • TABLE 09: DUEXIS US GRANTED PATENTS, HORZON PHARMA
  • TABLE 10: DUEXIS US PATENT APPLICATIONS, HORIZON PHARMA
  • TABLE 11: PENNSAID 2% US GRANTED PATENTS, NUVO PHARMACEUTICALS
  • TABLE 12: PENNSAID 2% US PATENT APPLICATIONS, NUVO PHARMACEUTICALS
  • TABLE 13: VIVLODEX US GRANTED PATENTS, IROKO PHARMCEUTICALS
  • TABLE 14: VIVLODEX US APPLICATION PATENTS, IROKO PHARMACEUTICALS
  • TABLE 15: ZORVOLEX US GRANTED PATENTS, IROKO PHARMACEUTICALS
  • TABLE 16: ZORVOLEX US PATENT APPLICATIONS, IROKO PHARMCEUTICALS
  • TABLE 17: MONOVISC US PATENT APPLICATIONS, ANIKA THERAPEUTICS
  • TABLE 18: PHASE III MOLECULES IN THE OSTEOARTHRITIS PIPELINE
  • TABLE 19: PHASE 2 MOLECULES IN THE OSTEOARTHRITIS PIPELINE
  • TABLE 20: PHASE 1 MOLECULES IN THE OSTEOARTHRITIS PIPELINE
  • TABLE 21: PRECLINICAL STAGE MOLECULES IN THE OSTEOARTHRITIS PIPELINE
  • TABLE 22: EARLY R&D STAGE MOLECULES IN THE OSTEOARTHRITIS PIPELINE
  • TABLE 23: OSTEOARTHRITIS INACTIVE AND DISCONTINUED MOLECULES
  • TABLE 24: OSTEOARTHRITIS PIPELINE ANALYSIS BY INJECTABLE ROA
  • TABLE 25: OSTEOARTHRITIS PIPELINE ANALYSIS BY TOPICAL ROA
  • TABLE 26: OSTEOARTHRITIS PIPELINE ANALYSIS BY ORAL ROA
  • TABLE 27: OSTEOARTHRITIS PIPELINE ANALYSIS, ANTI-INFLAMMATORY DRUG CLASS
  • TABLE 28: ESTIMATED APPROVAL TIMELINES OF OSTEOARTHRITIS PIPELINE DRUGS
  • TABLE 29: AMPION PIVOTAL PHASE III TRIALS DESIGN
  • TABLE 30: RESULTS OF NEO6860
  • TABLE 31: KEY PHASE III ONGOING CLINICAL TRIALS
  • TABLE 32: PHASE II/III ONGOING CLINICAL TRIAL RESULT
  • TABLE 33: PHASE II ONGOING CLINICAL TRIALS
  • TABLE 34: PHASE I ONGOING CLINICAL TRIALS
  • TABLE 35: PHASE III PLANNED CLINICAL TRIALS
  • TABLE 36: PHASE II PLANNED CLINICAL TRIALS
  • TABLE 37: PHASE I PLANNED CLINICAL TRIALS
  • TABLE 38: RECENTLY COMPLETED PHASE III CLINICAL TRIALS (2015-2018)
  • TABLE 39: RECENTLY COMPLETED PHASE II/III CLINICAL TRIALS (2015-2018)
  • TABLE 40: RECENTLY COMPLETED PHASE II CLINICAL TRIALS (2015-2018)
  • TABLE 41: RECENTLY COMPLETED PHASE II/I CLINICAL TRIALS (2015-2018)
  • TABLE 42: RECENTLY COMPLETED PHASE I CLINICAL TRIALS (2015-2018)
  • TABLE 43: ONGOING POST-MARKETING SURVEILLANCE (PMS) STUDIES
  • TABLE 44: COMPLETED POST-MARKETING SURVEILLANCE (PMS) STUDIES (2015-2018)
  • TABLE 45: ASTRAZENECA PRODUCT PORTFOLIO
  • TABLE 46: R&D ACTIVITIES OF ASTRAZENECA
  • TABLE 47: CONFERENCES/EVENTS ATTENDED BY ASTRAZENECA
  • TABLE 48: RECENT DEVELOPMENTS MADE BY ASTRAZENECA
  • TABLE 49: ELI LILLY & COMPANY PRODUCT PORTFOLIO
  • TABLE 50: OTHER PHASE 2 AND PHASE 1 PROGRAM, ENDOCRINOLOGY THERAPY AREA
  • TABLE 51: OTHER PHASE 2 AND PHASE 1 PROGRAM, IMMUNOLOGY THERAPY AREA
  • TABLE 52: OTHER PHASE 2 AND PHASE 1 PROGRAM, NEURODEGENERATION AREA
  • TABLE 53: OTHER PHASE 2 AND PHASE 1 PROGRAM, ONCOLOGY THERAPY AREA
  • TABLE 54: R&D ACTIVITIES OF ELI LILLY & COMPANY
  • TABLE 55: CONFERENCES/EVENTS ATTENDED BY ELI LILLY & COMPANY
  • TABLE 56: RECENT DEVELOPMENTS MADE BY ELI LILLY & COMPANY
  • TABLE 57: PFIZER PRODUCT PORTFOLIO
  • TABLE 58: PHASE 2 AND PHASE 1 PROGRAM, INFLAMMATION AND IMMUNOLOGY AREA
  • TABLE 59: PHASE 2 AND PHASE 1 PROGRAM, INTERNAL MEDICINE
  • TABLE 60: PHASE 2 AND PHASE 1 PROGRAM, ONCOLOGY THERAPY AREA
  • TABLE 61: PRODUCTS UNDER DEVELOPMENT, RARE DISEASES
  • TABLE 62: VACCINES UNDER DEVELOPMENT
  • TABLE 63: BIOSIMILARS UNDER DEVELOPMENT
  • TABLE 64: DRUGS UNDER DEVELOPMENT IN OTHER AREAS OF FOCUS
  • TABLE 65: R&D ACTIVITIES OF PFIZER
  • TABLE 66: CONFERENCES/EVENTS ATTENDED BY PFIZER
  • TABLE 67: RECENT DEVELOPMENTS MADE BY PFIZER
  • TABLE 68: R&D ACTIVITIES OF FLEXION
  • TABLE 69: CONFERENCES/EVENTS ATTENDED BY FLEXION
  • TABLE 70: RECENT DEVELOPMENTS MADE BY FLEXION
  • TABLE 71: R&D ACTIVITIES OF VERICEL
  • TABLE 72: CONFERENCES/EVENTS ATTENDED BY VERICEL
  • TABLE 73: RECENT DEVELOPMENTS MADE BY VERICEL
  • TABLE 74: R&D ACTIVITIES OF IROKO
  • TABLE 75: CONFERENCES/EVENTS ATTENDED BY IROKO
  • TABLE 76: RECENT DEVELOPMENTS MADE BY IROKO
  • TABLE 77: R&D ACTIVITIES OF ANIKA THERAPEUTICS
  • TABLE 78: CONFERENCES/EVENTS ATTENDED BY ANIKA THERAPEUTICS
  • TABLE 79: RECENT DEVELOPMENTS MADE BY ANIKA THERAPEUTICS
  • TABLE 80: HORIZON PHARMA PRODUCT PORTFOLIO
  • TABLE 81: R&D ACTIVITIES OF HORIZON PHARMA
  • TABLE 82: CONFERENCES/EVENTS ATTENDED BY HORIZON PHARMA
  • TABLE 83: RECENT DEVELOPMENTS MADE BY HORIZON PHARMA
  • TABLE 84: COMMERCIAL OPPORTUNITES, NUVO PHARMACEUTICALS
  • TABLE 85: R&D ACTIVITIES OF NUVO PHARMACEUTICALS
  • TABLE 86: RECENT DEVELOPMENTS MADE BY NUVO PHARMACEUTICALS
  • TABLE 87: R&D ACTIVITIES OF KITOV PHARMACEUTICALS
  • TABLE 88: CONFERENCES/EVENTS ATTENDED BY KITOV PHARMACEUTICALS
  • TABLE 89: RECENT DEVELOPMENTS MADE BY KITOV PHARMACEUTICALS
  • TABLE 90: RECENT DEVELOPMENTS OF KOLON TISSUEGENE
  • TABLE 91: OTHER PHASE 1 AND PRECLINICAL PROGRAMS UNDER PIPELINE
  • TABLE 92: R&D ACTIVITIES OF SAMUMED
  • TABLE 93: RECENT DEVELOPMENTS MADE BY SAMUMED
  • TABLE 94: CONFERENCES/EVENTS ATTENDED BY SAMUMED
  • TABLE 95: RECENT DEVELOPMENTS MADE BY OLATEC
  • TABLE 96: R&D ACTIVITIES OF ORTHOTROPHIX
  • TABLE 97: CONFERENCES/EVENTS ATTENDED BY ORTHOTROPHIX
  • TABLE 98: DRUG PIPELINE, TECHFIELDS
  • TABLE 99: RECENT DEVELOPMENTS MADE BY TECHFIELDS
  • TABLE 100: ACQUISITIONS MADE BY EMBER THERAPEUTICS
  • TABLE 101: FUTURE MILESTONES OF ZYNERBA PHARMCEUTICALS
  • TABLE 102: RECENT DEVELOPMENTS MADE BY ZYNERBA PHARMACEUTICALS
  • TABLE 103: RECENT DEVELOPMENTS AND MILESTONES, BONE THERAPEUTICS
  • TABLE 104: RECENT DEVELOPMENTS AND MILESTONES OF LEVOLTA PHARMACEUTICALS
  • TABLE 105: RECENT DEVELOPMENTS AND MILESTONES OF CENTREXION THERAPEUTICS
  • TABLE 106: RECENT DEVELOPMENTS AND MILESTONES OF AMPIO PHARMACEUTICALS
  • TABLE 107: RECENT DEVELOPMENTS AND MILESTONES OF SYMIC BIO
  • TABLE 108: RECENT DEVELOPMENTS AND MILESTONES OF PARADIGM BIOPHARMA
  • TABLE 109: FUTURE MILESTONES OF PARADIGM BIOPHARMA

LIST OF FIGURES

  • FIGURE 01: KEY PIPELINE EVENTS, 2020-2035
  • FIGURE 02: OA GLOBAL EPIDEMIOLOGY FORECAST 2018-2025
  • FIGURE 03: US EPIDEMIOLOGY FORECAST 2018-2025
  • FIGURE 04: OSTEOARTHRITIS MERGERS & ACQUISITIONS BY DEAL TYPE (2004 - 2018)
  • FIGURE 05: GEOGRAPHY-WISE BREAKUP, DEAL MAKERS IN OSTEOARTHRITIS (2004 -2018)
  • FIGURE 06: ZILRETTA, US AND EX-US GRANTED PATENTS
  • FIGURE 07: ZILRETTA US AND EX-US APPLICATION PATENTS
  • FIGURE 08: DUEXIS, US AND EX-US GRANTED PATENTS
  • FIGURE 09: DUEXIS US AND EX-US PATENT APPLICATIONS
  • FIGURE 10: PENNSAID 2%, US AND EX-US GRANTED PATENTS
  • FIGURE 11: VIVLODEX, US AND EX-US GRANTED PATENTS
  • FIGURE 12: VIVLODEX US AND EX-US APPLICATION PATENTS
  • FIGURE 13: ZOVOLEX, US AND EX-US GRANTED PATENTS
  • FIGURE 14: MONOVISC US AND EX-US APPLICATION PATENTS
  • FIGURE 15: OSTEOARTHITIS PIPELINE ANALYSIS BY STAGES OF DEVELOPMENT
  • FIGURE 16: OSTEOARTHITIS PIPELINE ANALYSIS BY GEOGRAPHY
  • FIGURE 17: HSD COMPARISON, US V/S EU
  • FIGURE 18: OSTEOARTHITIS DRUG PIPELINE SPLIT BY ROA
  • FIGURE 19: OSTEOARTHITIS DRUGS PIPELINE, ROA V/S HSD
  • FIGURE 20: PIPELINE ANALYSIS BY INJECTABLES, SPLIT BY TECHNIQUE USED
  • FIGURE 21: INJECTABLES BY HSD SPLIT-UP
  • FIGURE 22: ORALS BY HSD SPLIT-UP
  • FIGURE 23: OSTEOARTHITIS DRUGS PIPELINE BY DIFFERENT DRUG CLASSES
  • FIGURE 24: ANTI-INFLAMMATORY DRUGS SPLIT BY HSD
  • FIGURE 25: AMPION PHASE III AP-003-A TRIAL RESULT
  • FIGURE 26: AMPION PHASE III AP-003-C TRIAL RESULT
  • FIGURE 27: TANEZUMAB PHASE III TRIAL EFFICACY RESULTS
  • FIGURE 28: WOMAC PAIN AND FUNCTION RESPONDERS TO SM04690 & PBO
  • FIGURE 29: UNILATERAL SYMPTOMATIC
  • FIGURE 30: UNILATERAL SYMPTOMATIC WITHOUT WIDESPREAD PAIN
  • FIGURE 31: PHASE III ONGOING TRIAL COMPLETION YEAR V/S OA TYPE
  • FIGURE 32: PHASE II/III ONGOING TRIAL COMPLETION YEAR V/S OA TYPE
  • FIGURE 33: PHASE II ONGOING TRIAL COMPLETION YEAR V/S OA TYPE
  • FIGURE 34: PHASE I ONGOING TRIAL COMPLETION YEAR V/S OA TYPE
  • FIGURE 35: KEY PHASE III PLANNED TRIAL COMPLETION YEAR V/S OA TYPE
  • FIGURE 36: RECENTLY COMPLETED PHASE III CLINICAL TRIALS (2015-2018)
  • FIGURE 37: RECENTLY COMPLETED PHASE II/III CLINICAL TRIALS (2015-2018)
  • FIGURE 38: RECENTLY COMPLETED PHASE II CLINICAL TRIALS (2015-2018)
  • FIGURE 39: RECENTLY COMPLETED PHASE II/I CLINICAL TRIALS (2015-2018)
  • FIGURE 40: RECENTLY COMPLETED PHASE I CLINICAL TRIALS (2015-2018)
  • FIGURE 41: ONGOING POST-MARKETING SURVEILLANCE (PMS) STUDIES
  • FIGURE 42: ONGOING POST-MARKETING SURVEILLANCE (PMS) STUDIES
  • FIGURE 43: FINANCIAL INFORMATION OF ASTRAZENECA
  • FIGURE 44: SWOT ANALYSIS OF ASTRAZENECA
  • FIGURE 45: FINANCIAL INFORMATION OF ELI LILLY & COMPANY
  • FIGURE 46: SWOT ANALYSIS OF ELI LILLY & COMPANY
  • FIGURE 47: FINANCIAL INFORMATION OF PFIZER
  • FIGURE 48: SWOT ANALYSIS OF PFIZER
  • FIGURE 49: FINANCIAL INFORMATION OF FLEXION
  • FIGURE 50: SWOT ANALYSIS OF FLEXION
  • FIGURE 51: FINANCIAL INFORMATION OF VERICEL
  • FIGURE 52: SWOT ANALYSIS OF VERICEL
  • FIGURE 53: SWOT ANALYSIS OF IROKO
  • FIGURE 54: FINANCIAL INFORMATION OF ANIKA THERAPEUTICS
  • FIGURE 55: SWOT ANALYSIS OF ANIKA THERAPEUTICS
  • FIGURE 56: FINANCIAL INFORMATION OF HORIZON PHARMA
  • FIGURE 57: SWOT ANALYSIS OF HORIZON PHARMA
  • FIGURE 58: FINANCIAL INFORMATION OF NUVO PHARMACEUTICALS
  • FIGURE 59: SWOT ANALYSIS OF NUVO PHARMACEUTICAL.
Back to Top